1. Home
  2. SEV vs ANIX Comparison

SEV vs ANIX Comparison

Compare SEV & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SEV

Aptera Motors Corp.

HOLD

Current Price

$2.14

Market Cap

103.2M

Sector

Industrials

ML Signal

HOLD

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$2.51

Market Cap

88.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SEV
ANIX
Founded
2019
1982
Country
United States
United States
Employees
46
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
103.2M
88.8M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
SEV
ANIX
Price
$2.14
$2.51
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$8.67
AVG Volume (30 Days)
228.4K
102.9K
Earning Date
05-16-2026
05-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
12.82
EPS
N/A
N/A
Revenue
N/A
$210,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$17,757.14
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.29
$2.44
52 Week High
$11.24
$5.46

Technical Indicators

Market Signals
Indicator
SEV
ANIX
Relative Strength Index (RSI) 28.63 32.14
Support Level $1.29 $2.44
Resistance Level $3.26 $3.13
Average True Range (ATR) 0.17 0.13
MACD -0.02 -0.03
Stochastic Oscillator 0.00 2.20

Price Performance

Historical Comparison
SEV
ANIX

About SEV Aptera Motors Corp.

Aptera Motors Corp engages in the development, production, and distribution of energy efficient solar-powered, battery-electric vehicles. The company has designed the Aptera vehicle to provide up to an estimated 40 miles per day by collecting energy from the sun and storing it in its proprietary battery pack. The company operates as a single reportable segment focused on the development of solar electric vehicles.

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

Share on Social Networks: